Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Generate Biomedicines, Inc.
GENB
NASDAQ·Financial Services·Asset Management·Mkt cap $2.1B
$17.36
▲ +5.24%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$11.00 - $18.18
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 30.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary machine learning platform for protein engineering
- Integrated computational and biohardware infrastructure
- Diverse protein modality expertise across multiple therapeutic areas
- First-mover advantage in generative biology space
Bear Case
1 risk
- Low volatility (beta 0.2).
Growth
Strong growth ahead
Advancement of GB-0895 through clinical trials for severe asthma market
Value
Deep value opportunity - significant discount to Asset Management peers
Momentum
Strong
+20.0% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying GENB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 6, 2026
MAY 7, 2026
Reported EPS of -$1.07 vs -$0.45 consensus (-137.8% surprise). Revenue of $7.2M vs $5.3M expected (+36.8%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-137.8%
Next: Aug 6, 2026
Revenue trend · last 1Q
—
Q1 26
$7.2M
Margins · last 1Q
Profit
-850.6%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$23.50
▲ +35.3% vs $17.36
Latest: Morgan Stanley · $22.00 · May 14, 2026
2 analysts covering